X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement November 06, 2023
Details:
Yondelis (trabectedin) is a novel, synthetically produced antitumor agent originally isolated from Ecteinascidia turbinata, that acts a DNA inhibitor. It is indicated for the treatment of of patients with unresectable or metastatic liposarcoma or leiomyosarcoma.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
Yondelis (trabectedin) binds guanine residues in the minor groove of DNA, forming adducts and resulting in a bending of the DNA helix triggering a cascade of events like DNA repair pathways, resulting in perturbation of the cell cycle and eventual cell death.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 17, 2023
Details:
Through the agreement, Johnson will obtain the rights to commercialize Yondelis (trabectedin), a marine-derived anticancer drug utilized for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Johnson & Johnson Innovative Medicine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 12, 2022
Details:
Yondelis-Generic (trabectedin) is a DNA inhibitor, small molecule drug candidate. It is being developed for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis-Generic
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 18, 2022
Details:
The Therapeutic Goods Administration has approved the use of YONDELIS (trabectedin), marketed by Specialised Therapeutics, "for the treatment of patients with unresectable or metastatic liposarcoma or leiomyosarcoma who received a prior anthracycline-containing regimen".
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 23, 2021
Details:
PharmaMar has granted to STADA a license to market the Yondelis® (trabectedin) marine-derived cancer treatment in 15 Middle East-North Africa countries. Yondelis® is marketed in several MENA countries for the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement November 17, 2020
Details:
Trabectedin is currently provided by Janssen to patients in Turkey for the treatment of Soft Tissue Sarcoma and, through this license, Onko will also pursue regulatory approval for the indication of relapsed ovarian cancer.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Onko Kocsel Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement August 10, 2020
Details:
Through agreement, Adium will be able to commercialize the marine-derived anticancer drug Yondelis (trabectedin), which is used in the treatment of soft tissue sarcoma and relapsed ovarian cancer.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Adium Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement July 27, 2020
Details:
EMA has recommended that the use of Yondelis (trabectedin) in treating ovarian cancer remain unchanged following a review of a study that investigated Yondelis as a third-line treatment in patients with ovarian cancer.
Lead Product(s): Trabectedin,Doxorubicin Hydrochloride,Dexamethasone
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 24, 2020
Details:
Under the agreement, Taiwan Toyo will distribute the new anti-cancer drug Yondelis (trabectedin), a newly synthesized anti-tumor drug derived from the sea squirt Ecteinascidia turbinata, in Taiwan, Hong Kong and Macau.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Yondelis
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: TOYO Pharmaceutical
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement June 09, 2020
Details:
PharmaMar will retain exclusive production rights for Yondelis®(trabectedin), which will be sold to Key Oncologics for its clinical and commercial use in South Africa, Namibia and Botswana.
Lead Product(s): Trabectedin
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Key Oncologics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement May 19, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
